
Precision Medicine in Oncology®
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News

Heather Wakelee, MD, discusses the latest developments with EGFR inhibitors and immunotherapy agents in non-small cell lung cancer.

The FDA granted a priority review in March to a new drug application for maintenance olaparib, and is scheduled to make its final decision on the PARP inhibitor before the end of the year.














Frontline osimertinib (Tagrisso) significantly improved progression-free survival versus standard of care in patients with locally-advanced or metastatic EGFR-positive non–small cell lung cancer.









Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types
5













































